Moxetumomab pasudotox
- Generic Name
- Moxetumomab pasudotox
- Brand Names
- Lumoxiti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1020748-57-5
- Unique Ingredient Identifier
- 2NDX4B6N8F
- Background
CD22 is a lineage-restricted B-cell antigen that is expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and Burkitt's lymphoma. The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 which specifically binds to CD22. This antibody was used to generate a reco...
- Indication
MxP is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies including treatment with a purine nucleoside analog. The use of this drug is not recommended in patients with severe renal impairment (CrCl < 29 ml/min).
...
- Associated Conditions
- Relapsed/Refractory Hairy Cell Leukemia
- Associated Therapies
- -
Cancer Antibody Drug Conjugates Market, Drugs Approval, Price, Sales & Clinical Trials
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.